Integral Diagnostics expects $790M in FY26 revenue
- Integral Diagnostics announced preliminary FY26 revenue expectations between $788 million and $790 million.
- The initial market reaction left the company's shares trading flat at $2.16.
- Integral Diagnostics stated that operational discipline supported its continued debt reduction trajectory.
Integral Diagnostics (ASX:IDX) expects preliminary FY26 revenue to reach between $788 million and $790 million.
The expected result compares against the $628 million recorded during the previous financial year.
Operating EBITDA for the period is expected to reach $164 million to $165 million. The company stated operating net profit after tax is projected to reach $47–48 million.
Integral Diagnostics indicated that group replacement and growth capital expenditure totalled approximately $50 million.
The company also appointed Jenny Martin as the company’s new CFO, effective Oct. 5.
Following the announcement, the Integral Diagnostics share price was unchanged at $2.16.
The business stated that its operating debt ratio improved to an estimated 2.3 times.
Frequently asked questions
More from Australia
Resurgent inflation pressures test key Australian consumer shares
The digital cart rush redefining Australian retail profit pools
Trans-Tasman insurers battle contract churn while defending profit margins
Capital battles heat up as takeover offers challenge listed housing operators
The equities fueling the next infrastructure supercycle
Crypto networks collide with sanctions in a fight for financial access
